NCT06479720View on ClinicalTrials.gov

Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder

PHASE4RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

June 16, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Effect of DrugUrinary Bladder, Overactive
Interventions
DRUG

Combined pharmacotherapy with Solifenacin and Mirabegron

Solifenacin (5mg) is anticholinergic and Mirabegron (25mg) is a beta-3 adrenergic agonist.

DRUG

Solifenacin with vaginal estrogen cream

Solifenacin (5mg) is anticholinergic. Premarin, vaginal conjugated equine estrogen vaginal cream (0.625 mg).

DRUG

Mirabegron with vaginal estrogen cream

Mirabegron (25mg) is a beta-3 adrenergic agonist. Premarin, vaginal conjugated equine estrogen vaginal cream (0.625 mg).

Trial Locations (1)

Unknown

RECRUITING

Mackay Memorial Hospital, Taipei

All Listed Sponsors
lead

Mackay Memorial Hospital

OTHER